Serum soluble tumor necrosis factor-like weak inducer of apoptosis is a potential biomarker for outcome prediction of patients with aneurysmal subarachnoid hemorrhage.

[1]  J. Cailhier,et al.  Innate immunity activation in the early brain injury period following subarachnoid hemorrhage , 2019, Journal of Neuroinflammation.

[2]  Ze Zhong,et al.  Serum soluble TWEAK levels in severe traumatic brain injury and its prognostic significance. , 2019, Clinica chimica acta; international journal of clinical chemistry.

[3]  H. Marquering,et al.  Radiological scales predicting delayed cerebral ischemia in subarachnoid hemorrhage: systematic review and meta-analysis , 2019, Neuroradiology.

[4]  J. Ranjeva,et al.  High levels of serum soluble TWEAK are associated with neuroinflammation during multiple sclerosis , 2019, Journal of Translational Medicine.

[5]  E. J. Lee,et al.  Tumor necrosis factor-like weak inducer of apoptosis induces inflammation in Graves’ orbital fibroblasts , 2018, PloS one.

[6]  Hirofumi Nishikawa,et al.  Matricellular proteins as possible biomarkers for early brain injury after aneurysmal subarachnoid hemorrhage , 2018, Neural regeneration research.

[7]  G. Hergenroeder,et al.  Early Brain Injury Associated with Systemic Inflammation After Subarachnoid Hemorrhage , 2018, Neurocritical Care.

[8]  C. Putterman,et al.  Intracerebroventricular administration of TNF-like weak inducer of apoptosis induces depression-like behavior and cognitive dysfunction in non-autoimmune mice , 2016, Brain, Behavior, and Immunity.

[9]  J. Grimm.  Aneurysmal Subarachnoid Hemorrhage: A Potentially Lethal Neurological Disease. , 2015, Journal of emergency nursing: JEN : official publication of the Emergency Department Nurses Association.

[10]  M. Schwartz,et al.  TNF-like weak inducer of apoptosis promotes blood brain barrier disruption and increases neuronal cell death in MRL/lpr mice. , 2015, Journal of autoimmunity.

[11]  J. Hernesniemi,et al.  Aneurysmal subarachnoid hemorrhage: pathobiology, current treatment and future directions , 2015, Expert review of neurotherapeutics.

[12]  Christian Humpel,et al.  Early brain injury after aneurysmal subarachnoid hemorrhage: a multimodal neuromonitoring study , 2015, Critical Care.

[13]  J. Vendrell,et al.  TWEAK: A New Player in Obesity and Diabetes , 2013, Front. Immunol..

[14]  C. Putterman,et al.  Neuropsychiatric Lupus, the Blood Brain Barrier, and the TWEAK/Fn14 Pathway , 2013, Front. Immunol..

[15]  P. Bartold,et al.  Expression of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor, fibroblast growth factor-inducible 14 protein (Fn14), in healthy tissues and in tissues affected by periodontitis. , 2010, Journal of periodontal research.

[16]  Jialing Wu,et al.  The Interaction between Tumor Necrosis Factor-Like Weak Inducer of Apoptosis and its Receptor Fibroblast Growth Factor-Inducible 14 Promotes the Recruitment of Neutrophils into the Ischemic Brain , 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[17]  C. Sommer,et al.  Induction of the cytokine TWEAK and its receptor Fn14 in ischemic stroke , 2008, Journal of the Neurological Sciences.

[18]  L. Burkly,et al.  TWEAK is expressed at the cell surface of monocytes during multiple sclerosis , 2008, Journal of leukocyte biology.

[19]  M. Yepes.  TWEAK and the Central Nervous System , 2007, Molecular Neurobiology.

[20]  M. Yepes.  Tweak and FN14 in central nervous system health and disease. , 2007, Frontiers in bioscience : a journal and virtual library.

[21]  L. Burkly,et al.  TWEAK—Fn14 Pathway Inhibition Protects the Integrity of the Neurovascular Unit during Cerebral Ischemia , 2007, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

[22]  L. Burkly,et al.  Anti-TWEAK monoclonal antibodies reduce immune cell infiltration in the central nervous system and severity of experimental autoimmune encephalomyelitis. , 2005, Clinical immunology.

[23]  D. Lawrence,et al.  A soluble Fn14-Fc decoy receptor reduces infarct volume in a murine model of cerebral ischemia. , 2005, The American journal of pathology.

[24]  M. Schwaninger,et al.  Tumor Necrosis Factor-Like Weak Inducer of Apoptosis-Induced Neurodegeneration , 2004, The Journal of Neuroscience.

[25]  M. Khrestchatisky,et al.  TWEAK is expressed by glial cells, induces astrocyte proliferation and increases EAE severity , 2002, Journal of Neuroimmunology.

[26]  R. Macdonald,et al.  Management of aneurysmal subarachnoid hemorrhage. , 2017, Handbook of clinical neurology.

[27]  I. Solaroglu,et al.  Early brain injury following aneurysmal subarachnoid hemorrhage: emphasis on cellular apoptosis. , 2012, Turkish neurosurgery.

[28]  John H. Zhang,et al.  Connecting the early brain injury of aneurysmal subarachnoid hemorrhage to clinical practice. , 2010, Turkish neurosurgery.

[29]  C. Drake,et al.  Report of World Federation of Neurological Surgeons Committee on a Universal Subarachnoid Hemorrhage Grading Scale. , 1988, Journal of neurosurgery.